Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nurexone Biologic Inc

NRX.V ✓ COMPLIANTFree checks used up today ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.36

▼ -7.41%

Market Cap $34.42M · Vol 37.00K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$34.42M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

22.22

Momentum

Beta

0.32

vs Market

52W High

$0.54

28.99% below

52W Low

$0.31

24.19% above

Volume

37.00K

Avg 14.96K

P/B

15.81

Price-to-book

ROE

N/A

Return on equity

Free Float

93.72%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Nurexone Biologic Inc (NRX.V) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NRX.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.09%

-25.37%

+2.04%

-15.25%

YTD

-24.24%

-31.51%

+64.53%

-9.09%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-6,384,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-195.71% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	15.81
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	96.40M

Technical Indicators

50-Day SMA	$0.43
200-Day SMA	$0.43
RSI (14)	22.22
Beta	0.32
52-Week High	$0.54
52-Week Low	$0.31

Volume Today	37.00K
Avg Daily Volume (30D)	14.96K
Relative Volume	2.47x
Volatility (10D)	58.05
Volatility (30D)	99.68
Free Float	93.72%

Analyst Consensus

N/A

Current Price $0.36

Mean Target N/A

52W Low$0.31 52W High$0.54

Current

Target

$0.31 $0.54

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG002CV5ZR1

ISINCA67059R1091

CountryIsrael

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.47% ONC BeOne Medicines AG -1.79% 068270.KS Celltrion, Inc. -2.26% MEDP Medpace Holdings, Inc. +1.13% CRL Charles River Laboratories International, Inc. +3.45%

Company Profile

Nurexone Biologic Inc is an Israel-based company engaged primarily in the pharmaceutical sector. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The Company focuses on research and development of pharmaceutical technologies.